Clinical Trials
84 trialsMolecular and Epidemiological Risk Factors in the Development of Gastric Cancer
The University of Texas Health Science Center at San Antonio
TOGAR
Baylor College of Medicine
PLATON
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
SURGIGAST
University Hospital, Lille
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
AM-003
University of Virginia
NeoRacing
Fudan University
IVANS
Fondazione IRCCS Policlinico San Matteo di Pavia
TOASTIT
Mayo Clinic
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
RESCUE-GC
Peking University Cancer Hospital & Institute
PECORINO
Ukrainian Society of Clinical Oncology
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
EQLVCPAL
Centre Hospitalier de la côte Basque
Cy-plus
Peking University
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Johns Hopkins University
Advanced Gastrointestinal Endoscopic Imaging
Stanford University
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
Rigshospitalet, Denmark
Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
Laval University
TORCH
University of Florida
EPSILON
Erasme University Hospital
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
GASTHER2
AC Camargo Cancer Center
SOHUG
Kangbuk Samsung Hospital
repeat
Harbin Medical University
OLFADIAG
Nouvelle Clinique Bonnefon
Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer
Jiangxi University of Traditional Chinese Medicine
LOGIC
University of Saskatchewan
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
First Affiliated Hospital Xi'an Jiaotong University
DOMICA
Poitiers University Hospital
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
M.D. Anderson Cancer Center
PembroMab
Western Regional Medical Center
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
FamGaCan
Radboud University Medical Center
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
China Medical University, China
AZD2014
Samsung Medical Center
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
CISCA
UMC Utrecht
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
Brown University
N1
CureOne
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
University of California, Irvine
mEGA
Georgetown University
FluoHeart
Helsinki University Central Hospital
IPEC-GC
Centre Hospitalier Universitaire de Besancon
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer
Medical University of South Carolina